Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures. This study assessed in vitro antibacterial activities and synergistic activities o...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-10, Vol.16 (10), p.e0258426-e0258426 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0258426 |
|---|---|
| container_issue | 10 |
| container_start_page | e0258426 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Wang, Fangzhou Zhou, Qian Yang, Xiuwen Bai, Yan Cui, Junchang |
| description | Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures. This study assessed in vitro antibacterial activities and synergistic activities of ceftazidime/avibactam alone and in combinations against KPC-Kp. In total, 70 isolates from 2 hospitals in Beijing were examined in our study. By using the agar dilution method and broth dilution method, we determined the minimum inhibitory concentration (MIC) of candidate antibiotics. Ceftazidime/avibactam demonstrated promising susceptibility against KPC-Kp (97.14%). Synergistic activities testing was achieved by checkerboard method and found ceftazidime/avibactam-amikacin displayed synergism in 90% isolates. Ceftazidime/avibactam-colistin displayed partial synergistic in 43% isolates, and ceftazidime/avibactam-tigecycline displayed indifference in 67% isolates. In time-kill assays, antibiotics at 1-fold MIC were mixed with bacteria at 1 x 10.sup.5 CFU/ml and Mueller-Hinton broth (MHB). Combinations of ceftazidime/avibactam with amikacin and tigecycline displayed better antibacterial effects than single drug. Ceftazidime/avibactam-colistin combination did not exhibit better effect than single drug. In KPC-Kp infections, susceptibility testing suggested that ceftazidime/avibactam may be considered as first-line choice. However, monotherapy is often inadequate in infection management. Thus, our study revealed that combination therapy including ceftazidime/avibactam colistin and ceftazidime/avibactam tigecycline may benefit than monotherapy in KPC-Kp treatment. Further pharmacokinetic/pharmacodynamic and mutant prevention concentration studies should be performed to optimize multidrug-regimens. |
| doi_str_mv | 10.1371/journal.pone.0258426 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2582105971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A678973902</galeid><doaj_id>oai_doaj_org_article_4327301612124de19a433cbaa743c552</doaj_id><sourcerecordid>A678973902</sourcerecordid><originalsourceid>FETCH-LOGICAL-c669t-7d69e33966bafffb5cc97ffeef61f467bbd9e703fdc06c83d3286baf1ed354073</originalsourceid><addsrcrecordid>eNqNk9tu1DAQhiMEoqXwBkhEQkIgsds4TpzkBqmqCqxaqRKnW2vijLPeOnYaO0uXN-StcNgF7aJeIF_49M0_Mx5PFD0nyZzQgpyu7DgY0PPeGpwnaV5mKXsQHZOKpjOWJvTh3vooeuLcKklyWjL2ODqiGcvKPGfH0c-LNegRvLImtjIWKD38UI3q8BTWqgbhoYtBBx8xmCZWJha2q5XZWnxXfhlDp25AKPM2XGnlfGAm1KsWxUZoNZm2oIzz8aXG2inUGuLe4NhZowBjAUMNPRrswOGsH2wzBrk2vpzvU_Vm8r5WfrBBu8PZjdI6xrseh7Az_mn0SIJ2-Gw3n0Rf3198Of84u7r-sDg_u5oJxio_KxpWIaUVYzVIKetciKqQElEyIjNW1HVTYZFQ2YiEiZI2NC0nlGBD8ywp6En0Yqvba-v4rgqOhwKkJMmrggRisSUaCyveh_Bg2HALiv8-sEPLYfBKaOQZTQuaEEZSkmYNkgoySkUNUGRU5HkatN7tvI11h40IiQ6gD0QPb4xa8taueZkH1SoPAq93AoO9HdF53iknphIYtOM27pKkZTmhL_9B789uR7UQElBG2uBXTKL8jBVlVdAqmeKe30OF0WCnRPhOUoXzA4M3BwaB8XjnWxid44vPn_6fvf52yL7aY5cI2i-d1eP0f90hmG1BMVjnBpR_H5kkfOq4P6_Bp47ju46jvwAXqCIE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2582105971</pqid></control><display><type>article</type><title>Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wang, Fangzhou ; Zhou, Qian ; Yang, Xiuwen ; Bai, Yan ; Cui, Junchang</creator><contributor>Algammal, Abdelazeem Mohamed</contributor><creatorcontrib>Wang, Fangzhou ; Zhou, Qian ; Yang, Xiuwen ; Bai, Yan ; Cui, Junchang ; Algammal, Abdelazeem Mohamed</creatorcontrib><description>Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures. This study assessed in vitro antibacterial activities and synergistic activities of ceftazidime/avibactam alone and in combinations against KPC-Kp. In total, 70 isolates from 2 hospitals in Beijing were examined in our study. By using the agar dilution method and broth dilution method, we determined the minimum inhibitory concentration (MIC) of candidate antibiotics. Ceftazidime/avibactam demonstrated promising susceptibility against KPC-Kp (97.14%). Synergistic activities testing was achieved by checkerboard method and found ceftazidime/avibactam-amikacin displayed synergism in 90% isolates. Ceftazidime/avibactam-colistin displayed partial synergistic in 43% isolates, and ceftazidime/avibactam-tigecycline displayed indifference in 67% isolates. In time-kill assays, antibiotics at 1-fold MIC were mixed with bacteria at 1 x 10.sup.5 CFU/ml and Mueller-Hinton broth (MHB). Combinations of ceftazidime/avibactam with amikacin and tigecycline displayed better antibacterial effects than single drug. Ceftazidime/avibactam-colistin combination did not exhibit better effect than single drug. In KPC-Kp infections, susceptibility testing suggested that ceftazidime/avibactam may be considered as first-line choice. However, monotherapy is often inadequate in infection management. Thus, our study revealed that combination therapy including ceftazidime/avibactam colistin and ceftazidime/avibactam tigecycline may benefit than monotherapy in KPC-Kp treatment. Further pharmacokinetic/pharmacodynamic and mutant prevention concentration studies should be performed to optimize multidrug-regimens.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0258426</identifier><identifier>PMID: 34648556</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Amikacin ; Antibacterial activity ; Antibacterial agents ; Antibiotics ; Bacteria ; Biology and Life Sciences ; Carbapenemase ; Ceftazidime ; Colistin ; Complications and side effects ; Dilution ; Disease susceptibility ; Enzymes ; Evaluation ; Experiments ; Gram-negative bacteria ; Health aspects ; Health risks ; Infections ; Klebsiella ; Klebsiella pneumoniae ; Life sciences ; Medicine and Health Sciences ; Minimum inhibitory concentration ; Mutation ; Pathogens ; Patient outcomes ; Pharmaceuticals ; Pharmacodynamics ; Pharmacokinetics ; Pharmacology ; Respiratory diseases ; Synergism ; Tigecycline</subject><ispartof>PloS one, 2021-10, Vol.16 (10), p.e0258426-e0258426</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Wang et al 2021 Wang et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c669t-7d69e33966bafffb5cc97ffeef61f467bbd9e703fdc06c83d3286baf1ed354073</citedby><cites>FETCH-LOGICAL-c669t-7d69e33966bafffb5cc97ffeef61f467bbd9e703fdc06c83d3286baf1ed354073</cites><orcidid>0000-0002-0031-8735</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516195/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516195/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,2914,23846,27903,27904,53770,53772,79347,79348</link.rule.ids></links><search><contributor>Algammal, Abdelazeem Mohamed</contributor><creatorcontrib>Wang, Fangzhou</creatorcontrib><creatorcontrib>Zhou, Qian</creatorcontrib><creatorcontrib>Yang, Xiuwen</creatorcontrib><creatorcontrib>Bai, Yan</creatorcontrib><creatorcontrib>Cui, Junchang</creatorcontrib><title>Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment</title><title>PloS one</title><description>Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures. This study assessed in vitro antibacterial activities and synergistic activities of ceftazidime/avibactam alone and in combinations against KPC-Kp. In total, 70 isolates from 2 hospitals in Beijing were examined in our study. By using the agar dilution method and broth dilution method, we determined the minimum inhibitory concentration (MIC) of candidate antibiotics. Ceftazidime/avibactam demonstrated promising susceptibility against KPC-Kp (97.14%). Synergistic activities testing was achieved by checkerboard method and found ceftazidime/avibactam-amikacin displayed synergism in 90% isolates. Ceftazidime/avibactam-colistin displayed partial synergistic in 43% isolates, and ceftazidime/avibactam-tigecycline displayed indifference in 67% isolates. In time-kill assays, antibiotics at 1-fold MIC were mixed with bacteria at 1 x 10.sup.5 CFU/ml and Mueller-Hinton broth (MHB). Combinations of ceftazidime/avibactam with amikacin and tigecycline displayed better antibacterial effects than single drug. Ceftazidime/avibactam-colistin combination did not exhibit better effect than single drug. In KPC-Kp infections, susceptibility testing suggested that ceftazidime/avibactam may be considered as first-line choice. However, monotherapy is often inadequate in infection management. Thus, our study revealed that combination therapy including ceftazidime/avibactam colistin and ceftazidime/avibactam tigecycline may benefit than monotherapy in KPC-Kp treatment. Further pharmacokinetic/pharmacodynamic and mutant prevention concentration studies should be performed to optimize multidrug-regimens.</description><subject>Amikacin</subject><subject>Antibacterial activity</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Biology and Life Sciences</subject><subject>Carbapenemase</subject><subject>Ceftazidime</subject><subject>Colistin</subject><subject>Complications and side effects</subject><subject>Dilution</subject><subject>Disease susceptibility</subject><subject>Enzymes</subject><subject>Evaluation</subject><subject>Experiments</subject><subject>Gram-negative bacteria</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Infections</subject><subject>Klebsiella</subject><subject>Klebsiella pneumoniae</subject><subject>Life sciences</subject><subject>Medicine and Health Sciences</subject><subject>Minimum inhibitory concentration</subject><subject>Mutation</subject><subject>Pathogens</subject><subject>Patient outcomes</subject><subject>Pharmaceuticals</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Respiratory diseases</subject><subject>Synergism</subject><subject>Tigecycline</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tu1DAQhiMEoqXwBkhEQkIgsds4TpzkBqmqCqxaqRKnW2vijLPeOnYaO0uXN-StcNgF7aJeIF_49M0_Mx5PFD0nyZzQgpyu7DgY0PPeGpwnaV5mKXsQHZOKpjOWJvTh3vooeuLcKklyWjL2ODqiGcvKPGfH0c-LNegRvLImtjIWKD38UI3q8BTWqgbhoYtBBx8xmCZWJha2q5XZWnxXfhlDp25AKPM2XGnlfGAm1KsWxUZoNZm2oIzz8aXG2inUGuLe4NhZowBjAUMNPRrswOGsH2wzBrk2vpzvU_Vm8r5WfrBBu8PZjdI6xrseh7Az_mn0SIJ2-Gw3n0Rf3198Of84u7r-sDg_u5oJxio_KxpWIaUVYzVIKetciKqQElEyIjNW1HVTYZFQ2YiEiZI2NC0nlGBD8ywp6En0Yqvba-v4rgqOhwKkJMmrggRisSUaCyveh_Bg2HALiv8-sEPLYfBKaOQZTQuaEEZSkmYNkgoySkUNUGRU5HkatN7tvI11h40IiQ6gD0QPb4xa8taueZkH1SoPAq93AoO9HdF53iknphIYtOM27pKkZTmhL_9B789uR7UQElBG2uBXTKL8jBVlVdAqmeKe30OF0WCnRPhOUoXzA4M3BwaB8XjnWxid44vPn_6fvf52yL7aY5cI2i-d1eP0f90hmG1BMVjnBpR_H5kkfOq4P6_Bp47ju46jvwAXqCIE</recordid><startdate>20211014</startdate><enddate>20211014</enddate><creator>Wang, Fangzhou</creator><creator>Zhou, Qian</creator><creator>Yang, Xiuwen</creator><creator>Bai, Yan</creator><creator>Cui, Junchang</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0031-8735</orcidid></search><sort><creationdate>20211014</creationdate><title>Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment</title><author>Wang, Fangzhou ; Zhou, Qian ; Yang, Xiuwen ; Bai, Yan ; Cui, Junchang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c669t-7d69e33966bafffb5cc97ffeef61f467bbd9e703fdc06c83d3286baf1ed354073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Amikacin</topic><topic>Antibacterial activity</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Biology and Life Sciences</topic><topic>Carbapenemase</topic><topic>Ceftazidime</topic><topic>Colistin</topic><topic>Complications and side effects</topic><topic>Dilution</topic><topic>Disease susceptibility</topic><topic>Enzymes</topic><topic>Evaluation</topic><topic>Experiments</topic><topic>Gram-negative bacteria</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Infections</topic><topic>Klebsiella</topic><topic>Klebsiella pneumoniae</topic><topic>Life sciences</topic><topic>Medicine and Health Sciences</topic><topic>Minimum inhibitory concentration</topic><topic>Mutation</topic><topic>Pathogens</topic><topic>Patient outcomes</topic><topic>Pharmaceuticals</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Respiratory diseases</topic><topic>Synergism</topic><topic>Tigecycline</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Fangzhou</creatorcontrib><creatorcontrib>Zhou, Qian</creatorcontrib><creatorcontrib>Yang, Xiuwen</creatorcontrib><creatorcontrib>Bai, Yan</creatorcontrib><creatorcontrib>Cui, Junchang</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Fangzhou</au><au>Zhou, Qian</au><au>Yang, Xiuwen</au><au>Bai, Yan</au><au>Cui, Junchang</au><au>Algammal, Abdelazeem Mohamed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment</atitle><jtitle>PloS one</jtitle><date>2021-10-14</date><risdate>2021</risdate><volume>16</volume><issue>10</issue><spage>e0258426</spage><epage>e0258426</epage><pages>e0258426-e0258426</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures. This study assessed in vitro antibacterial activities and synergistic activities of ceftazidime/avibactam alone and in combinations against KPC-Kp. In total, 70 isolates from 2 hospitals in Beijing were examined in our study. By using the agar dilution method and broth dilution method, we determined the minimum inhibitory concentration (MIC) of candidate antibiotics. Ceftazidime/avibactam demonstrated promising susceptibility against KPC-Kp (97.14%). Synergistic activities testing was achieved by checkerboard method and found ceftazidime/avibactam-amikacin displayed synergism in 90% isolates. Ceftazidime/avibactam-colistin displayed partial synergistic in 43% isolates, and ceftazidime/avibactam-tigecycline displayed indifference in 67% isolates. In time-kill assays, antibiotics at 1-fold MIC were mixed with bacteria at 1 x 10.sup.5 CFU/ml and Mueller-Hinton broth (MHB). Combinations of ceftazidime/avibactam with amikacin and tigecycline displayed better antibacterial effects than single drug. Ceftazidime/avibactam-colistin combination did not exhibit better effect than single drug. In KPC-Kp infections, susceptibility testing suggested that ceftazidime/avibactam may be considered as first-line choice. However, monotherapy is often inadequate in infection management. Thus, our study revealed that combination therapy including ceftazidime/avibactam colistin and ceftazidime/avibactam tigecycline may benefit than monotherapy in KPC-Kp treatment. Further pharmacokinetic/pharmacodynamic and mutant prevention concentration studies should be performed to optimize multidrug-regimens.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>34648556</pmid><doi>10.1371/journal.pone.0258426</doi><tpages>e0258426</tpages><orcidid>https://orcid.org/0000-0002-0031-8735</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-10, Vol.16 (10), p.e0258426-e0258426 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2582105971 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Amikacin Antibacterial activity Antibacterial agents Antibiotics Bacteria Biology and Life Sciences Carbapenemase Ceftazidime Colistin Complications and side effects Dilution Disease susceptibility Enzymes Evaluation Experiments Gram-negative bacteria Health aspects Health risks Infections Klebsiella Klebsiella pneumoniae Life sciences Medicine and Health Sciences Minimum inhibitory concentration Mutation Pathogens Patient outcomes Pharmaceuticals Pharmacodynamics Pharmacokinetics Pharmacology Respiratory diseases Synergism Tigecycline |
| title | Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A58%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20ceftazidime/avibactam%20alone%20and%20in%20combination%20with%20amikacin,%20colistin%20and%20tigecycline%20against%20Klebsiella%20pneumoniae%20carbapenemase-producing%20K.%20pneumoniae%20by%20in%20vitro%20time-kill%20experiment&rft.jtitle=PloS%20one&rft.au=Wang,%20Fangzhou&rft.date=2021-10-14&rft.volume=16&rft.issue=10&rft.spage=e0258426&rft.epage=e0258426&rft.pages=e0258426-e0258426&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0258426&rft_dat=%3Cgale_plos_%3EA678973902%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2582105971&rft_id=info:pmid/34648556&rft_galeid=A678973902&rft_doaj_id=oai_doaj_org_article_4327301612124de19a433cbaa743c552&rfr_iscdi=true |